ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

orelabrutinib

Also written as “ICP-022”, “Orelabrutinib” and “ICP-248+Orelabrutinib”.

Its studies are mostly in Lymphoma, Mantle-Cell · Lupus Erythematosus, Systemic · Multiple Sclerosis, Chronic Progressive · Purpura, Thrombocytopenic, Idiopathic · Lymphoma, Large B-Cell, Diffuse, led by 2 companies.

Drug pageOrelabrutinib: every studyAll 95 studies of it, academic ones too, with its approvals, label and forms.
Furthest: phase 3, since Oct 1, 202027 company-led studies, 13 open or runningLicense: InnoCare → Zenas BioPharma, Oct 2025Next primary completion: Aug 31, 2028 (phase 3)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
InnoCare Pharma2511 open or runningphase 3since Oct 1, 2020Jun 12, 2017Aug 31, 2028phase 3 · NCT06082102
Zenas BioPharma (USA)its history only22 open or runningphase 3since Jul 3, 2025Jul 3, 2025Jun 2030phase 3 · NCT07299019

How these companies relate

From the companies’ own releases and filings, each linked; the registry does not say.

History and studies of InnoCare Pharma only; the figures above count every company.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). A diamond marks a license, acquisition or co-development, from the companies’ own releases and filings. An open circle marks the day WHO proposed its name. Dates ahead are the sponsors’ estimates.

Not listed one by one: 11 earlier studies, Jun 12, 2017 to Jun 16, 2020.

  1. Dec 9, 2019Named orelabrutinibINNProposed as its International Nonproprietary Name in WHO's List 122 · before, ICP-022
  2. Oct 1, 2020Phase 3 study in Leukemia, Lymphocytic, Chronic, B-CellNCT04578613 · 218 planned · China
  3. Jan 8, 2021Phase 2 study in Multiple Sclerosis, Relapsing-RemittingNCT04711148 · 160 enrolled · United States, China, Poland and more
  4. Sep 15, 2021Phase 3 study in Treatment-naїve Mantle Cell LymphomaNCT05051891 · 3 enrolled · China
  5. Dec 20, 2021Phase 2 study in Purpura, Thrombocytopenic, IdiopathicNCT05232149 · 30 enrolled · China
  6. Jan 29, 2022Phase 3 study in Lymphoma, Large B-Cell, DiffuseNCT05234684 · 150 planned · China
  7. Mar 25, 2022Phase 1 study in Healthy PersonNCT05316857 · 36 enrolled · China
  8. Nov 11, 2022Phase 1 study in Healthy SubjectNCT05660720 · 48 enrolled · China
  9. Dec 14, 2022Phase 1 study in Hepatic ImpairmentNCT05684653 · 34 planned · China
  10. Jan 10, 2023Phase 2 study in Lupus Erythematosus, SystemicNCT05688696 · 186 planned · China
  11. Jan 12, 2023Phase 1 study in Hematologic NeoplasmsNCT05728658 · 191 planned · China
  12. Jul 11, 2023Phase 2 study in Lymphoma, Mantle-CellNCT05978739 · 40 enrolled · China
  13. Aug 15, 2023Phase 3 study in Chronic Primary Immune Thrombocytopenia (ITP)NCT06004856 · 195 planned · China
  14. Oct 8, 2023Phase 3 study in Lymphoma, B-Cell, Marginal ZoneNCT06082102 · 324 planned · China
  15. Apr 9, 2024Phase 3 study in Lymphoma, Mantle-CellNCT06363994 · 476 planned · China
  16. Oct 8, 2025Zenas BioPharma licensed it from InnoCareLicenseMultiple sclerosis worldwide, and other uses outside cancer outside Greater China and Southeast Asia · announced · Zenas BioPharma and InnoCare (release)

Ahead

  1. Aug 31, 2028Primary completion: phase 3 study in Lymphoma, B-Cell, Marginal ZoneNCT06082102
  2. Jun 25, 2031Primary completion: phase 3 study in Lymphoma, Mantle-CellNCT06363994

TargetBeta

BTK →read by rule
“A small molecule inhibitor of Bruton's tyrosine kinase (BTK; Bruton agammaglobulinemia tyrosine kinase) ”NCIt, by rule
“Tyrosine-protein kinase BTK inhibitor”ChEMBL 37, by rule

Other programs on BTK

ProgramCompanyFurthest phaseStudies
ibrutinibruleJohnson & Johnsonphase 478
acalabrutinibruleAstraZenecaphase 455
zanubrutinibruleBeOne Medicinesphase 435
pirtobrutinibruleEli Lillyphase 430
ritlecitinibrulePfizerphase 342
rilzabrutinibruleSanofiphase 323
evobrutinibruleMerck KGaA, Darmstadt, Germanyphase 320
fenebrutinibHoffmann-La Rochephase 318
nemtabrutinibMerckphase 316
rocbrutinibruleLupeng Pharmaceuticalphase 315
tirabrutinibruleGilead Sciencesphase 313
birelentinibruleDizal Pharmaceuticalsphase 312

Studies

All 25 InnoCare Pharma leads, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT06363994Lymphoma, Mantle-Cell · China3RecruitingJun 25, 2031476
NCT06082102Lymphoma, B-Cell, Marginal Zone · China3RecruitingAug 31, 2028324
NCT06004856Chronic Primary Immune Thrombocytopenia (ITP) · China3RecruitingDec 31, 2025195
NCT05978739Lymphoma, Mantle-Cell · China2CompletedDec 10, 202440
NCT05728658Hematologic Neoplasms · China1RecruitingAug 30, 2025191
NCT05688696Lupus Erythematosus, Systemic · China2RecruitingAug 25, 2025186
NCT05684653Hepatic Impairment · China1RecruitingDec 30, 202334
NCT05660720Healthy Subject · China1UNKNOWNJun 30, 202348
NCT05316857Healthy Person · China1CompletedJan 4, 202236
NCT05234684Lymphoma, Large B-Cell, Diffuse · China3RecruitingJul 30, 2024150
NCT05232149Purpura, Thrombocytopenic, Idiopathic · China2UNKNOWNDec 30, 202330
NCT05051891Treatment-naїve Mantle Cell Lymphoma · China3CompletedJun 30, 20253
NCT04711148Multiple Sclerosis, Relapsing-Remitting · United States, China, Poland and more2Active, not recruitingFeb 25, 2026160
NCT04578613Leukemia, Lymphocytic, Chronic, B-Cell · China3RecruitingDec 30, 2024218
NCT04441450Healthy Volunteers · China–CompletedAug 6, 20196
NCT04440059Waldenstrom's Macroglobulinemia Recurrent · China2CompletedJan 9, 202447
NCT04438044Recurrence · China2UNKNOWNDec 31, 202361
NCT04438005Lymphoma, Large B-Cell, Diffuse · China2CompletedNov 5, 20213
NCT04305197Lupus Erythematosus, Systemic · China2CompletedApr 28, 202260
NCT04304040B-cell Lymphoma Recurrent · China2Active, not recruitingDec 30, 202543
NCT04014205Part 1:r/r B-cell Malignancies · United States, Israel, Poland and more2Active, not recruitingJun 30, 202681
NCT03797456MZL · China2CompletedDec 27, 2023111
NCT03494179Lymphoma, Mantle-Cell · China2CompletedApr 10, 2020106
NCT03493217CLL/SLL · China2UNKNOWNDec 31, 2022100
NCT03189017Lupus Erythematosus, Systemic · Australia1CompletedFeb 5, 201864

How it is read

Names in the registry

  • “ICP-022”, 11 entries
  • “Orelabrutinib”, 7 entries
  • “ICP-248+Orelabrutinib”, 3 entries
  • “Orelabrutinib High dose”, 1 entry
  • “Orelabrutinib Low dose”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.